Natural killer T (NKT) cells: Immunophenotype, functional characteristics and significance in clinical practice

  • Olga V. Lebedinskaya
  • Nelly K. Akchmatova
  • Irina O. Chikileva
  • Irina Zh. Shubina
  • Mikhail V. Kiselevsky


Natural killer T cells are lymphocytes that express both T-cell and natural killer-cell markers. Natural killer T cells are found in parenchymal organs such as liver, lungs, spleen etc and a small number are found in peripheral blood. Natural killer T cells comprise a significant part of leukocyte infiltrates that occur in liver and other organs of patients with cancer or infectious diseases. These cells have a large impact on the functional activity of effectors of anti-tumor and anti-infectious immunity.


NKT cells IL-12 cytokines immunophenotype 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Abo T, Kawamura T, Watanabe H (2000) Physiological responses of extrathymic T cells in the liver. Immunol Rev 174(2):135–149PubMedCrossRefGoogle Scholar
  2. [2]
    Akhmatova NK, Kuzovlev EN, Lebedinskaya OV et al. (2006) Cytotoxic activity of natural killer T-(NKT) cells in mice with tumor-affected liver. Bull Exp Biol and Med 141(1):76–79.Google Scholar
  3. [3]
    Ali Tahir SM, Cheng O, Shaulov A et al. (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167: 4046–4050.Google Scholar
  4. [4]
    Ananias RZ, Rodrigues EG, Braga EG et al. (2007) Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl/6 mice: major NKT cell recruitment and increased cytotoxicity. Scand J Immunol 65(6):538–548.PubMedCrossRefGoogle Scholar
  5. [5]
    Apostolou I, Takahama Y, Belmant C et al. (1999) Murine natural killer T (NKT) cells contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci USA 96(9):5141–5146.PubMedCrossRefGoogle Scholar
  6. [6]
    Arrunategui-Correa V, Lenz L, Kim HS (2004) CD1d-independent regulation of NKT cell migration and cytokine production upon Listeria monocytogenes infection. Cell Immunol 232(1–2):38–48.PubMedCrossRefGoogle Scholar
  7. [7]
    Carlens S, Gilljam M, Chambers BJ et al. (2001) A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Human Immunol 62(4):1092–1098.CrossRefGoogle Scholar
  8. [8]
    Chang YJ, Huang JR, Tsai YC et al. (2007) Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci USA 104(25):10299–304.PubMedCrossRefGoogle Scholar
  9. [9]
    Crowe NY, Smyth MJ, Godfrey DI (2002) A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196(1): 119–127.PubMedCrossRefGoogle Scholar
  10. [10]
    Crowe NY, Uldrich AP, Kyparissoudis K et al. (2003) Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T Cells. J Immunol 171:4020–4027.PubMedGoogle Scholar
  11. [11]
    Davydov MI, Normantovich VA, Kiselevsky MV et al. (2000) Adoptive immunotherapy in malignant effusions: clinical laboratory study. Russian Oncol J 6:14–17.Google Scholar
  12. [12]
    Dhodapkar MV, Geller MD, Chang DH et al. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197(12):1667–1676.PubMedCrossRefGoogle Scholar
  13. [13]
    Emoto M, Kaufmann SH (2003) Liver NKT cells: an account of heterogeneity. Trends Immunol 24(7):368–369.CrossRefGoogle Scholar
  14. [14]
    Exley MA, Koziel MJ (2004) To be or not to be NKT: Natural Killer T Cells in the Liver. Hepatol 40(5):1033–1040.CrossRefGoogle Scholar
  15. [15]
    Fuji N, Ueda Y, Fujiwara H et al. (2000) Antitumor effect of α-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 6(8):3380–3387.PubMedGoogle Scholar
  16. [16]
    Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nature Immunol 3:867–874.CrossRefGoogle Scholar
  17. [17]
    Fujii S, Shimizu K, Smith C et al. (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J Exp Med 198(2):267–279.PubMedCrossRefGoogle Scholar
  18. [18]
    Giaccone G, Punt SJ, Ado Y et al. (2002) A phase I study of the natural killer T-cell ligand alpha-Galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709.PubMedGoogle Scholar
  19. [19]
    Godfrey DI, Hammond KJ, Poulton LD et al. (2000) NKT cells: facts, functions and fallacies. Immunol Today 21:573–583.PubMedCrossRefGoogle Scholar
  20. [20]
    Godfrey DI, MacDonald HR, Kronenberg M et al. (2004) NKT cells: what’s in a name? Nature Rev Immunol 4(3):231–237.CrossRefGoogle Scholar
  21. [21]
    Godfrey DL, Kronenberg M (2004) Going both ways: Immune regulation via CD1dp-dependent NKT cells. Clin Invest 114:1379–1388.Google Scholar
  22. [22]
    Golden-Mason L, O’Farrely C (2002) Having it all? Stem cells, haematopoiesis and lymphopoiesis in adult human liver. Immunol Cell Biol 80(1):45–51.PubMedCrossRefGoogle Scholar
  23. [23]
    Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al. (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195(5):617–624.PubMedCrossRefGoogle Scholar
  24. [24]
    Hayakawa Y, Takeda H, Yagita H et al. (2001) Critical contribution of IFN-gamma and NK cells, but not perforin- mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 31(6): 1720–1727.PubMedCrossRefGoogle Scholar
  25. [25]
    Hayakawa Y, Godfrey DI, Smyth MJ (2004) Alpha-galactosylceramide: potential immunomodulatory activity and future application. Curr Med Chem 11(2):241–252.PubMedCrossRefGoogle Scholar
  26. [26]
    Hong SM, Scherer DC, Singh N et al. (1999) Lipid antigen presentation in the immune system: lessons learned from CD 1 d knockout mice. Immunol Rev 169(1):31–44.PubMedCrossRefGoogle Scholar
  27. [27]
    Ikeda H, Chamoto K, Tsuji T et al. (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95(9):697–703.PubMedCrossRefGoogle Scholar
  28. [28]
    Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192(7):921–930.PubMedCrossRefGoogle Scholar
  29. [29]
    Kasper HU, Drebber U, Zur Hausen A et al. (2003) Dominance of CD4+ alpha/beta T-cells and inferior role of innate immune reaction in the liver metastases. Anticancer Res 23(4): 3175–3181.PubMedGoogle Scholar
  30. [30]
    Kawakami K, Kinjo Y, Uezu K et al. (2001) Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol (Baltimore, Md.: 1950) 167(11):6525–6532.Google Scholar
  31. [31]
    Kawano T, Cui J, Koezuka Y et al. (1997) CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 278(5343):1626–1629.PubMedCrossRefGoogle Scholar
  32. [32]
    Kawano T, Nakayama T, Kamada N et al. (1999) Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59:5102–5105.PubMedGoogle Scholar
  33. [33]
    Kenna T, Mason LG, Porcelli SA et al. (2003) NKT cells from normal and tumor-bearing human liver are phenotypically and functionally distinct from murine NKT cells. J Immunol 166(11):6578–6584.Google Scholar
  34. [34]
    Kenna T, O’Brien M, Hogan AE et al. (2007) CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver. Cancer Immunol Immunother 56(4): 563–572.PubMedCrossRefGoogle Scholar
  35. [35]
    Kitamura H, Iwakabe K, Yahata T et al. (1999) The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189(7):1121–1127.PubMedCrossRefGoogle Scholar
  36. [36]
    Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annual rev Immunol 23:877–900.CrossRefGoogle Scholar
  37. [37]
    Kronenberg M, Gapin L (2002) The unconventional lifestyle of NKT cells. Nature Rev Immunol 2(8):557–568.Google Scholar
  38. [38]
    Lebedinskaya OV, Kiselevsky MV, Lebedinskaya EA, Donenko FV (2006) Cytoimmunochemical characteristics of leukocyte infiltrates in different sites of murine liver with metastatic process. Curr Sci Technol 5:32–33.Google Scholar
  39. [39]
    Lebedinskaya OV, Patlusova ES, Lebedinskaya EA, et al. (2006) Morphological characteristics and reaction of hepatic lymphoid tissue of patients with metastatic process and hepatitis B. Achiev Curr Nat Sci 5:52.Google Scholar
  40. [40]
    Lebedinskaya OV, Patutko Yu I, Zabezhinsky DA et al. (2005) Morphological functional characteristics of natural killer T-cells (NKT) in patients with tumor-affected liver. Siberian Oncol J 3:24–31.Google Scholar
  41. [41]
    Lucas M, Gadola S, Meier U et al. (2003) Frequency and phenotype of Circulating Vα 24/Vβ 11 double-positive natural killer cells during hepatitis C infection. J Virol 77(3): 2251–2257.PubMedCrossRefGoogle Scholar
  42. [42]
    Matsuda JL, Gapin L, Baron JL et al. (2003) Mouse V14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 100(14):8395–8400.PubMedCrossRefGoogle Scholar
  43. [43]
    Matsuda JL, Naidenko OV, Gapin L et al. (2000) Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using CD1d Tetramers. J Exp Med 192(5):205–212.CrossRefGoogle Scholar
  44. [44]
    Metelitsa LS, Naidenko OV, Kant A et al. (2001) Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167: 3114–3122.PubMedGoogle Scholar
  45. [45]
    Motohashi S, Kobayashi S, Ito T et al. (2002) Preserved IFN-alpha production of circulating V alpha 24 NKT cells in primary lung cancer patients. Int J Cancer 102(2):159–165.PubMedCrossRefGoogle Scholar
  46. [46]
    Nakagawa R, Nagafune I, Tazunoki Y et al. (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J Immunol 166(11):6578–6584.PubMedGoogle Scholar
  47. [47]
    Nieda M, Okai M, Tazbirkova A et al. (2004) Therapeutic activation of V{alpha}24+V{beta}11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2):383–389.PubMedCrossRefGoogle Scholar
  48. [48]
    Nishikawa H, Kato T, Tanida K et al. (2003) CD4+\CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100(19):10902–10906.PubMedCrossRefGoogle Scholar
  49. [49]
    Norris S, Doherty DG, Collins C et al. (1999) Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogeous and include Vα 24-JαQ and γδT cell receptor bearing cells. Human Immunol 60:20–31.CrossRefGoogle Scholar
  50. [50]
    Ostrand-Rosenberg S, Clements VK, Terabe M et al. (2002) Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is INF-gamma dependent. J Immunol 169: 5796–5804.PubMedGoogle Scholar
  51. [51]
    Park SH, Kyin T, Bendelas A, Carnaud C (2003) The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170(3):1197–1201.PubMedGoogle Scholar
  52. [52]
    Paschenkov MV, Pinegin BV (2001) Major features of dendritic cells. Immunology 22:7–16.Google Scholar
  53. [53]
    Pillai AB, George TI, Dutt S et al. (2007) Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 178(10):6242–6251.PubMedGoogle Scholar
  54. [54]
    Schmieg J, Yang G, Franck RW, Tsuji M (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 198(11): 1631–1641.PubMedCrossRefGoogle Scholar
  55. [55]
    Seino K, Motohashi S, Fujisawa T et al. (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97(9):807–812.PubMedCrossRefGoogle Scholar
  56. [56]
    Sidobre S, Naidenko OV, Sim BC et al. (2002) The V14 NKT Cell TCR Exhibits High-Affinity Binding to a Glycolipid/CD1d Complex. J Immunol 169:1340–1348.PubMedGoogle Scholar
  57. [57]
    Singh AK, Yang JQ, Parekh VV et al. (2005) The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 35(4):1143–1154.PubMedCrossRefGoogle Scholar
  58. [58]
    Smiley ST, Lanthier PA, Couper KN et al. (2005) Exacerbated susceptibility to infection-stimulated immunopathology in CD1d-deficient mice. J Immunol 174(12):7904–7911.PubMedGoogle Scholar
  59. [59]
    Smyth MJ, Thia KY, Street SE et al. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191(4):661–668.PubMedCrossRefGoogle Scholar
  60. [60]
    Smyth MJ, Godfrey DI (2000) NKT cells and tumor immunity–a double-edged sword. Nature Immunol 1:459–460.CrossRefGoogle Scholar
  61. [61]
    Smyth MJ, Crowe NY, Takeda K et al. (2002) NKT cells - conductors of tumor immunity? Curr Opin Immunol 14:165–171.PubMedCrossRefGoogle Scholar
  62. [62]
    Spadaro M, Curcio C, Varadhachary A et al. (2007) Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. Cancer Res 67(13):6425–6432.PubMedCrossRefGoogle Scholar
  63. [63]
    Stober D, Jomantaite I, Schirmbeck R, Peimann J (2003) NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol 170(5): 2540–2548.PubMedGoogle Scholar
  64. [64]
    Su Z, Segura M, Morgan K et al. (2005) Impairment of protective immunity to blood-stage malaria by concurrent nematode infection. Inf and immunity 73(6):3531–3539.CrossRefGoogle Scholar
  65. [65]
    Swann JB, Coquet JM, Smyth MJ, Godfrey DI (2007) CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol 314:293–323.PubMedCrossRefGoogle Scholar
  66. [66]
    Terabe M, Matsui S, Noben-Trauth N et al. (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature immunol 1(6): 515–520.CrossRefGoogle Scholar
  67. [67]
    Trobonjaca Z, Leithauser F, Moller P et al. (2001) Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-γ release by liver NKT cells. J Immunol 167(3):1413–1422.PubMedGoogle Scholar
  68. [68]
    Trobonjaca Z, Kroger A, Stober D et al. (2002) Activating immunity in the liver. II. IFN-β attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 168(8):3763–3770.PubMedGoogle Scholar
  69. [69]
    Varma TK, Lin CY, Toliver-Kinsky TE et al. (2002) Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors. Clin Diagn Lab Immunol 9(3):530–554.PubMedCrossRefGoogle Scholar
  70. [70]
    Vershinina MYu, Khalturina EO, Donenko FV et al. (2004) Comparative functional and immunophenotype characteristics of lymphokine-activated killers (LAK), generated from natural killer T- (NKT) cells from patients with tumor-affected liver. Vestnik RAMS 12:32–36.Google Scholar
  71. [71]
    Wilson SB, Delovitch TL (2003) Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nature Rev Immunol 3:211–222.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Olga V. Lebedinskaya
    • 1
  • Nelly K. Akchmatova
    • 2
  • Irina O. Chikileva
    • 3
  • Irina Zh. Shubina
    • 3
  • Mikhail V. Kiselevsky
    • 3
  1. 1.Department of Histology Embryology and CytologyEA Vagner Perm Medical AcademyPermRussia
  2. 2.II Metchnikov Research Institute of Vaccines and Serum Laboratory of Therapeutic Vaccines MoscowRussia
  3. 3.Laboratory of Cell ImmunityNN Blokhin Russian Cancer Research Center RAMSMoscowRussia

Personalised recommendations